ScreenerHero

FAB Fusion Antibodies plc

LSE · GB · Healthcare · Biotechnology · fusionantibodies.com
11.25GBp0.00%Mkt Cap: 15.30M $P/E: —

Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies for cancer and infectious diseases in the United Kingdom, the rest of …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated - Common Stock
$127.85BUSDP/E 29.4
MRNA
Moderna, Inc. - Common Stock
$75.86BUSD
REGN
Regeneron Pharmaceuticals, Inc. - Common Stock
$75.69BUSDP/E 18.2
ARGX
argenx SE - American Depositary Shares
$57.51BUSDP/E 35.1
ARGX
argenx SE
$55.24BUSDP/E 36.1
RVMD
Revolution Medicines, Inc. - Common Stock
$44.29BUSD
UCB
UCB SA
$41.63BUSDP/E 17.7
ONC
BeOne Medicines Ltd. - American Depositary Shares
$40.51BUSDP/E 63.9
RPRX
Royalty Pharma plc - Class A Ordinary Shares
$33.03BUSDP/E 30.7
ALNY
Alnylam Pharmaceuticals, Inc. - Common Stock
$29.40BUSDP/E 38.3
ROIV
Roivant Sciences Ltd. - Common Shares
$25.80BUSD
BNTX
BioNTech SE - American Depositary Shares
$24.34BUSD
INSM
Insmed Incorporated - Common Stock
$24.27BUSD
INCY
Incyte Corporation - Common Stock
$23.37BUSDP/E 14.7
GMAB
Genmab A/S
$21.61BUSDP/E 29.3
GMAB
Genmab A/S - American Depositary Shares
$21.69BUSDP/E 27.4
JAZZ
Jazz Pharmaceuticals plc - Ordinary Shares
$15.30BUSDP/E 16.1
ASND
Ascendis Pharma A/S - Ordinary Share
$14.99BUSDP/E 17.8
EXEL
Exelixis, Inc. - Common Stock
$14.47BUSDP/E 18.4
SMMT
Summit Therapeutics Inc. - Common Stock
$13.37BUSD

Key Statistics

Company
Market Cap15.30M USD
Enterprise Value14.51M USD
Revenue (TTM)2.29M USD
Gross Profit1.34M USD
Net Income (TTM)-1.25M USD
Revenue/Share0.02 GBp
Last Price11.25 GBp
Fiscal Year EndMar 2026
MR QuarterMar 2026
Employees27
CountryGB
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-12.50
PEG—
EV/EBITDA-12.63
EV/Revenue6.33
P/S6.67
P/B8.65
EPS (TTM)-0.01
EPS (Forward)-0.01
52W Range
0.000056% of range20.00
52W High20.00 GBp
52W Low0.0000 GBp
Profitability
Gross Margin58.34%
Oper. Margin-44.73%
EBITDA Margin-50.10%
Profit Margin-54.45%
ROE-70.84%
ROA-42.15%
Growth
Revenue Growth67.80%
Earnings Growth—
Cash Flow & Leverage
Operating CF-1.21M USD
CapEx (TTM)65.22K USD
FCF Margin-35.34%
FCF Yield-5.30%
Net Debt-773.91K USD
Net Debt/EBITDA0.67
Balance Sheet
Debt/Equity0.20
Current Ratio2.82
Quick Ratio2.08
Book Value/Sh0.01 GBp
Cash/Share0.0080 GBp
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 GBp
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.125.16M
Float110.05M
Insiders12.37%
Institutions26.36%
Technical
SMA 5011.01 (+2.2%)
SMA 20012.63 (-10.9%)
Beta1.24
S&P 52W Chg14.58%
Avg Vol (30d)488.13K
Avg Vol (10d)376.36K
Technical Indicators
RSI (14)49.3
MACD0.1667
MACD Signal0.1668
MACD Hist.-0.0001
BB Upper12.67 GBp
BB Middle11.36 GBp
BB Lower10.04 GBp
BB Width23.15%
ATR (14)1.129 GBp
Vol Ratio (20d)0.87x